Publication
Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Authors not recorded
Tumour Biol2016PMID 26596839stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugPaclitaxelcivic_curation1.00
- geneMYD88civic_curation1.00
- variantMYD88 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26596839
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| MYD88 Overexpression1 | ||||||||
| Paclitaxel | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 2 | accepted | EID734In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-l… (full text at CIViC) PMID 26596839 · Xiang et al., 2016 · Open in CIViC | civic |